DB07268

JNK1 inhibitor CAS# 929007-72-7

DB07268

Catalog No. BCC1519----Order now to get a substantial discount!

Product Name & Size Price Stock
DB07268: 5mg $276 In Stock
DB07268: 10mg Please Inquire In Stock
DB07268: 20mg Please Inquire Please Inquire
DB07268: 50mg Please Inquire Please Inquire
DB07268: 100mg Please Inquire Please Inquire
DB07268: 200mg Please Inquire Please Inquire
DB07268: 500mg Please Inquire Please Inquire
DB07268: 1000mg Please Inquire Please Inquire
Related Products
  • JNK-IN-7

    Catalog No.:BCC1672
    CAS No.:1408064-71-0
  • JNK-IN-8

    Catalog No.:BCC1673
    CAS No.:1410880-22-6
  • CC-401 hydrochloride

    Catalog No.:BCC1458
    CAS No.:1438391-30-0
  • AS 602801

    Catalog No.:BCC1369
    CAS No.:848344-36-5
  • CC-930

    Catalog No.:BCC1459
    CAS No.:899805-25-5

Quality Control of DB07268

Number of papers citing our products

Chemical structure

DB07268

3D structure

Chemical Properties of DB07268

Cas No. 929007-72-7 SDF Download SDF
PubChem ID 16058637 Appearance Powder
Formula C17H15N5O2 M.Wt 321.33
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 32 mg/mL (99.59 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 2-[[2-(3-hydroxyanilino)pyrimidin-4-yl]amino]benzamide
SMILES C1=CC=C(C(=C1)C(=O)N)NC2=NC(=NC=C2)NC3=CC(=CC=C3)O
Standard InChIKey QHPKKGUGRGRSGA-UHFFFAOYSA-N
Standard InChI InChI=1S/C17H15N5O2/c18-16(24)13-6-1-2-7-14(13)21-15-8-9-19-17(22-15)20-11-4-3-5-12(23)10-11/h1-10,23H,(H2,18,24)(H2,19,20,21,22)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of DB07268

DescriptionDB07268 is a potent and selective JNK1 inhibitor with an IC50 value of 9 nM.In Vitro:DB07268 (Compound 2b) also inhibits CHK1, PAK4, AKT1, and ERK2 with IC50s of 0.82 μM, 5.5 μM, 15 μM, and 25 μM, respectively[1].

References:
[1]. Liu M, et al. Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72.

DB07268 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

DB07268 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of DB07268

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.1121 mL 15.5603 mL 31.1207 mL 62.2413 mL 77.8016 mL
5 mM 0.6224 mL 3.1121 mL 6.2241 mL 12.4483 mL 15.5603 mL
10 mM 0.3112 mL 1.556 mL 3.1121 mL 6.2241 mL 7.7802 mL
50 mM 0.0622 mL 0.3112 mL 0.6224 mL 1.2448 mL 1.556 mL
100 mM 0.0311 mL 0.1556 mL 0.3112 mL 0.6224 mL 0.778 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on DB07268

IC50: 9 nM for JNK1

DB07268 is a JNK1 inhibitor. The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein kinase family. Three JNK isoforms (JNK1, 2 and 3) have been identified. There is growing evidences indicating that activation of the JNK activity is involved in a number of human disease settings. Therefore, considerable efforts have been directed toward the identification of JNK inhibitors suitable for clinical development.

In vitro: The selectivity data of DB07268 against a panel of kinases has been tested. Results showed that DB07268 had some degree of selectivity over quite a few kinases with the exceptions of PLK, CHK1, and CK2. Although d DB07268 showed submicromolar potency against these three kinases, it still appeared to exhibit at least 70- to 90-fold greater potency against JNK1 than PLK, CHK1, and CK2 [1].

In vivo: Several analogs of DB07268 were profiled in vivo. These compounds had a range of exposure in rats and mice. Some had excellent brain penetration despite having poor rat pharmacokinetics, while others had a more balanced profile. Unfortunately, the most potent analog exhibited poor rat pk demonstrated by a short half-life, low oral absorption and poor brain penetration. One DB07268 analog likely exhibited modest rat pk with low clearance and decent oral absorption. This analog also showed modest brain penetration [1].

Clinical trial: So far, no clinical study has been reported.

References:
[1] Liu M,Wang S,Clampit JE,Gum RJ,Haasch DL,Rondinone CM,Trevillyan JM,Abad-Zapatero C,Fry EH,Sham HL,Liu G.  Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett.2007 Feb 1;17(3):668-72. Epub 2006 Nov 2.
[2] Romain Nol, Youseung Shin, Xinyi Song, Yuanjun He, Marcel Koenig, Weimin Chen, Yuan Yuan Ling, Li Lin, Claudia H.  Ruiz, Phil LoGrasso, Michael D. Cameron, Derek R. Duckett, Theodore M. Kamenecka. Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-Jun N-terminal kinase inhibitors.Bioorg Med Chem Lett. 2011 May 1; 21(9): 2732–2735.

Featured Products
New Products
 

Description

DB07268 is a potent and selective JNK1 inhibitor with an IC50 value of 9 nM.

Keywords:

DB07268,929007-72-7,Natural Products,JNK, buy DB07268 , DB07268 supplier , purchase DB07268 , DB07268 cost , DB07268 manufacturer , order DB07268 , high purity DB07268

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: